Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Triterpene Prodrug Design for Targeted OSCC Therapy
2026-09-17
The reference study developed a carrier-free, self-assembled prodrug from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. Its central innovation is a thioketal-linked glycyrrhetinic acid dimer that responds to tumor-associated reactive oxygen species, enabling drug release while glycyrrhetinic acid amplifies oxidative stress and supports further release.
-
HOBt in Peptide Coupling and Medicinal Chemistry
2026-09-17
HOBt supports high-fidelity amide bond formation across peptide synthesis and small-molecule discovery, especially when stereochemical integrity and mild activation matter. This practical guide connects HOBt handling with the indazole glucagon receptor antagonist workflow reported in the literature, including optimization checkpoints and troubleshooting.
-
Panobinostat Drives Calcineurin Degradation in Myeloma
2026-09-16
The 2016 JCI Insight study identified the calcineurin catalytic subunit PPP3CA as a clinically relevant vulnerability in multiple myeloma and showed that panobinostat promotes its degradation through disruption of HSP90 chaperone support. Combining calcineurin-directed and HDAC-inhibitor strategies enhanced antimyeloma activity, reduced osteoclast formation, and provided a mechanistic framework for studying bortezomib resistance.
-
KR-12 Design: Structure, Activity, and Translation
2026-09-16
The 2024 review presents KR-12 as a compact LL-37-derived platform whose sequence, termini, topology, conjugates, and delivery format can be systematically redesigned. Its findings connect membrane activity with anti-biofilm, endotoxin-neutralizing, immune-regulatory, and biomaterials applications while emphasizing assay context, stability, and translational limitations.
-
KP.3 RBD mRNA Vaccine Protects Mice
2026-09-15
Guan and colleagues evaluated a nucleoside-modified, lipid nanoparticle-encapsulated mRNA vaccine encoding the Omicron KP.3 receptor-binding domain in a structured spike-derived context. The candidate generated broadly neutralizing antibodies against several Omicron subvariants and protected mice from KP.3 challenge, while also showing a positive relationship between serum neutralization and protection.
-
Tetrahydromagnolol: Peripheral CB2 Research
2026-09-15
Tetrahydromagnolol combines submicromolar CB2 activity with measurable GPR55 antagonism, making it useful for separating receptor-driven signaling from downstream cytoskeletal effects. This guide translates that pharmacology into reproducible GPCR, ERM, inflammation, and cell-motility workflows while clearly distinguishing established evidence from testable extensions.
-
Gap19: Selective Connexin 43 Hemichannel Blocker
2026-09-14
Gap19 enables researchers to separate Cx43 hemichannel signaling from gap junction communication in astrocyte, macrophage, and ischemia models. Its value is greatest in workflows that pair ATP, inflammatory, and pathway readouts with explicit selectivity and viability controls.
-
Exendin-4 Workflows for Beta Cell Research
2026-09-14
Exendin-4, also known as Exenatide, provides a practical GLP-1 receptor agonist stimulus for connecting cAMP signaling with insulin secretion, neuronal protection, and metabolic phenotyping. This guide translates the compound’s documented properties and yeast-expression research into reproducible assay workflows, controls, and troubleshooting decisions.
-
Thymoquinone Workflow for Cardiotoxicity Research
2026-09-13
Build a translational workflow around Thymoquinone for modeling doxorubicin-associated cardiac injury, integrating function, redox biology, ferroptosis-related markers, and mitochondrial structure. The approach also shows how to distinguish genuine pathway-linked protection from solvent effects, precipitation, or nonspecific cytotoxicity.
-
Ceruletide Workflows for Pancreatic Fibrosis
2026-09-12
Ceruletide, also known as Caerulein, provides a controlled CCK-receptor stimulus for pancreatic function research, fibrosis modeling, and gastrointestinal physiology studies. This practical guide connects model induction with MFGE8–ANXA1–SMAD2/3 readouts, formulation controls, and troubleshooting strategies.
-
(S)-Mephenytoin for CYP2C19 Organoid Assays
2026-09-11
(S)-Mephenytoin provides a practical activity benchmark for CYP2C19 in human intestinal organoid-derived epithelial cells. This workflow connects substrate turnover, 4-hydroxy metabolite formation, and model quality control for translational pharmacokinetic studies.
-
RWJ 67657: A Decision Framework for p38 Assays
2026-09-11
RWJ 67657, also known as JNJ-3026582, is a selective p38α/p38β inhibitor for dissecting inflammatory signaling. This guide connects its cytokine pharmacology with phosphatase-aware assay design, helping researchers distinguish direct pathway inhibition from downstream phenotype.
-
Acifran Workflows for HCAR2/HCAR3 Signaling
2026-09-10
Acifran provides a practical bridge between receptor structure, Gi-linked cAMP assays, and lipid metabolism research. This workflow shows how to use it as a paired HCAR2/HCAR3 probe, control compound handling, and troubleshoot the most common sources of weak or misleading signaling data.
-
Dextran sulfate sodium salt: DSS Colitis Workflow
2026-09-10
Build a reproducible DSS colitis study around controlled epithelial injury, fresh solution handling, and recovery-phase sampling. This workflow connects practical model optimization with the GPR35-KLF5 repair circuitry described in recent ulcerative colitis research.
-
TLS, CD40–STING Competition, and B-Cell Activation in ESCC
2026-09-09
The reference study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-positive B-cell activation as a key biological feature. Its mechanistic model proposes that CD40 and STING compete for TRAF2, reshaping non-canonical NF-κB signaling and providing a framework for biomarker development and pathway-focused validation.